MX2019009356A - Sulfinilpiridinas y su uso en el tratamiento del cancer. - Google Patents

Sulfinilpiridinas y su uso en el tratamiento del cancer.

Info

Publication number
MX2019009356A
MX2019009356A MX2019009356A MX2019009356A MX2019009356A MX 2019009356 A MX2019009356 A MX 2019009356A MX 2019009356 A MX2019009356 A MX 2019009356A MX 2019009356 A MX2019009356 A MX 2019009356A MX 2019009356 A MX2019009356 A MX 2019009356A
Authority
MX
Mexico
Prior art keywords
treatment
sulfinylpyridines
cancer
compounds
cancers
Prior art date
Application number
MX2019009356A
Other languages
English (en)
Inventor
Pelcman Benjamin
Orwar Owe
Stafford William
Anderson Kjell
Original Assignee
Oblique Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oblique Therapeutics Ab filed Critical Oblique Therapeutics Ab
Publication of MX2019009356A publication Critical patent/MX2019009356A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Se proporcionan compuestos de la Fórmula I (I) (ver formula I) o sales de estos aceptables desde el punto de vista farmacéutico, en donde L, R1, R2, R3, R4 y n tienen significados proporcionados en la descripción, en donde los 10 compuestos son útiles en el tratamiento de tipos de cáncer.
MX2019009356A 2017-02-07 2018-02-07 Sulfinilpiridinas y su uso en el tratamiento del cancer. MX2019009356A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762455645P 2017-02-07 2017-02-07
PCT/GB2018/050342 WO2018146468A1 (en) 2017-02-07 2018-02-07 Sulfinylpyridines and their use in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2019009356A true MX2019009356A (es) 2019-09-19

Family

ID=61226605

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009356A MX2019009356A (es) 2017-02-07 2018-02-07 Sulfinilpiridinas y su uso en el tratamiento del cancer.

Country Status (12)

Country Link
US (2) US11208384B2 (es)
EP (1) EP3580204A1 (es)
JP (1) JP2020507624A (es)
KR (1) KR20190115011A (es)
CN (1) CN110382465A (es)
AU (1) AU2018218518B2 (es)
BR (1) BR112019016258A2 (es)
CA (1) CA3051644A1 (es)
MA (1) MA47450A (es)
MX (1) MX2019009356A (es)
RU (1) RU2019127896A (es)
WO (1) WO2018146468A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
CN110382464A (zh) 2017-02-07 2019-10-25 欧比力克治疗公司 烃基磺酰基取代的吡啶和其在癌症治疗中的用途
CN110382465A (zh) * 2017-02-07 2019-10-25 欧比力克治疗公司 亚磺酰基吡啶和其在癌症治疗中的用途
AU2018218519B2 (en) 2017-02-07 2021-08-05 Oblique Therapeutics Ab Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
US11168069B2 (en) 2017-02-07 2021-11-09 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
US20210038577A1 (en) * 2018-02-12 2021-02-11 Cinda Pharma Ab Thioredoxin reductase inhibitors for use in the treatment of cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3064846D1 (en) 1979-12-19 1983-10-20 Duphar Int Res New nitrothiophenes, method of preparing the new compounds, as well as fungicidal and/or bactericidal compositions on the basis of the new compounds
US4456469A (en) 1980-03-07 1984-06-26 E. I. Du Pont De Nemours And Company Pyridyl sulfone herbicides
AU543161B2 (en) 1980-03-07 1985-04-04 E.I. Du Pont De Nemours And Company Pyrimidine or s.triazine derivatives
US4791127A (en) 1985-10-07 1988-12-13 Nippon Kayaku Kabushiki Kaisha Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides
DE3812177A1 (de) * 1988-04-13 1989-10-26 Bayer Ag 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung
US5945425A (en) 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
DE19531148A1 (de) 1995-08-24 1997-02-27 Basf Ag Fungizide Pyridin-2-yl-Derivate
US6069144A (en) 1995-08-24 2000-05-30 Basf Aktiengesellschaft N-heterocyclic compounds, intermediate products used to prepare them, agents containing them and their use in antifungal applications
US6191280B1 (en) 1997-05-30 2001-02-20 Basf Aktiengesellschaft Method for producing substituted thiopyridines
US6284923B1 (en) 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
JP2001519345A (ja) 1997-10-02 2001-10-23 メルク エンド カムパニー インコーポレーテッド プレニルタンパク質トランスフェラーゼの阻害剤
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6191170B1 (en) 1998-01-13 2001-02-20 Tularik Inc. Benzenesulfonamides and benzamides as therapeutic agents
PT930302E (pt) 1998-01-16 2003-07-31 Hoffmann La Roche Derivados de benzo-sulfona
CA2401778C (en) 2000-02-29 2010-12-21 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003068744A1 (fr) 2002-02-18 2003-08-21 Ishihara Sangyo Kaisha, Ltd. Derives de la pyridine ou leurs sels, et inhibiteurs de production de citokine renfermant ces derives
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US7037902B2 (en) * 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
US7915293B2 (en) 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
ATE415397T1 (de) 2004-06-04 2008-12-15 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
US20060019967A1 (en) * 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
GB0426313D0 (en) 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
WO2006083692A2 (en) 2005-01-28 2006-08-10 Mount Sinai Schoool Of Medicine Methods of identifying modulators of bromodomains
GB0504828D0 (en) 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
EP1976495A2 (en) 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
US20100009973A1 (en) 2006-04-28 2010-01-14 Avexa Limited Integrase Inhibitors 3
WO2007137255A2 (en) * 2006-05-22 2007-11-29 Thioredoxin Systems Ab Bacterial thioredoxin reductase inhibitors and methods for use thereof
NZ582772A (en) 2007-07-17 2012-06-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN101723932B (zh) 2008-10-31 2013-11-20 北京以岭生物工程技术有限公司 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途
AU2010253820A1 (en) * 2009-05-28 2011-12-22 President And Fellows Of Harvard College N,N-diarylurea compounds and N,N'-diarylthiourea compounds as inhibitors of translation initiation
CN102753177A (zh) 2009-08-17 2012-10-24 纪念斯隆-凯特琳癌症中心 热休克蛋白结合化合物、组合物以及其制备和使用方法
WO2011099502A1 (ja) 2010-02-10 2011-08-18 公立大学法人横浜市立大学 神経選択的転写抑制因子NRSFに特異的に結合するmSin3B に結合する化合物の利用
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
EP2609089A1 (en) 2010-08-27 2013-07-03 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
EP2811990B1 (en) 2012-02-10 2017-10-25 The Board of Regents of The University of Texas System Modulators of exchange proteins directly activated by camp (epacs)
WO2015006458A1 (en) 2013-07-10 2015-01-15 Boehringer Ingelheim International Gmbh Novel chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes
CN104672214B (zh) 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
CN105503827B (zh) 2014-10-11 2019-09-24 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备方法和用途
CN104987324B (zh) 2015-06-04 2018-05-04 湖北生物医药产业技术研究院有限公司 作为alk抑制剂的嘧啶衍生物
CN105085483B (zh) 2015-06-04 2019-01-01 湖北生物医药产业技术研究院有限公司 激酶抑制剂及其应用
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
CN110382464A (zh) 2017-02-07 2019-10-25 欧比力克治疗公司 烃基磺酰基取代的吡啶和其在癌症治疗中的用途
US11168069B2 (en) 2017-02-07 2021-11-09 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
AU2018218519B2 (en) 2017-02-07 2021-08-05 Oblique Therapeutics Ab Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
CN110382465A (zh) * 2017-02-07 2019-10-25 欧比力克治疗公司 亚磺酰基吡啶和其在癌症治疗中的用途

Also Published As

Publication number Publication date
KR20190115011A (ko) 2019-10-10
CN110382465A (zh) 2019-10-25
BR112019016258A2 (pt) 2020-04-07
US11208384B2 (en) 2021-12-28
WO2018146468A1 (en) 2018-08-16
JP2020507624A (ja) 2020-03-12
EP3580204A1 (en) 2019-12-18
AU2018218518B2 (en) 2022-03-17
RU2019127896A (ru) 2021-03-09
CA3051644A1 (en) 2018-08-16
RU2019127896A3 (es) 2021-05-18
US20220177430A1 (en) 2022-06-09
US20200024233A1 (en) 2020-01-23
AU2018218518A1 (en) 2019-08-15
MA47450A (fr) 2019-12-18

Similar Documents

Publication Publication Date Title
MX2019009356A (es) Sulfinilpiridinas y su uso en el tratamiento del cancer.
MX2019009266A (es) Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer.
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX2018001576A (es) Piridinas y su uso en el tratamiento del cancer.
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
MX2019009351A (es) Piridinas sustituidas con heteroarilsulfonilo y su uso en el tratamiento del cancer.
MX2019009354A (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer.
MX2020011465A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX2015010128A (es) Derivados de piridazinona macrociclicos.
MX2018010993A (es) Derivados de icariina e icaritina.
MX2018008362A (es) Derivados de quinolin-2-ona.
PH12019550224A1 (en) Antitumoral compounds
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
WO2017027357A8 (en) Pyridazinones and their use in the treatment of cancer
MX2018001575A (es) Compuestos triciclicos y su uso en el tratamiento del cancer.
AU2016363719A8 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
MX2019009362A (es) Compuestos heterociclicos novedosos y sus usos en la prevencion o el tratamiento de infecciones bacterianas.
EA201992557A1 (ru) Противоопухолевые соединения